Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Soricimed Biopharma Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner. The prosecution is concentrated in 1 distinct art unit. This suggests that the 1 pending office action is being reviewed by a specific technical group within the Biotechnology & Pharmaceuticals field.
The busiest examiner for the company is SULLIVAN, DENNIS JOHN. This examiner is responsible for 1 busiest examiner pending office action. This single action represents the total 1 pending office action for the company. For the practitioner, the 1 distinct examiner, SULLIVAN, DENNIS JOHN, is the sole individual reviewing the company's current filings. The focus within 1 distinct art unit means the 1 pending office action will be subject to the specific examination practices of that unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, DENNIS JOHN | 1 | 57.6% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605112 | TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR TREATING CANCERS | SULLIVAN, DENNIS JOHN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605112 | TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR TREATING CANCERS | SULLIVAN, DENNIS JOHN | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18605112 | TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR TREATING CANCERS | SULLIVAN, DENNIS JOHN | 1642 | §103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSoricimed Biopharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dennis John Sullivan has the most, with 1 of Soricimed Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
